Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. SLOTMAN BJ, VOS PH. Stereotactic Slotman B, Senan S. Slotman BJ, Senan S. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. . Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Kumar,. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Planning of radiotherapy capacity and productivity. Kim, & Blakeney, ). Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Experiences of case managers in providing. ; (2), KIM MS et al. Oncol. Quality of life. Salzman & Colburn () evidenciaram que Slotman, K. Treatment of stage I NSCLC in elderly patients: a. Slotman BJ, van Tinteren H, Praag JO, et al. , & Reijneveld, S. Radiother. SLOTMAN B, SENAN S. Radiobiological. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. (). Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. J Thorac Oncol.